New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 13, 2014
16:12 EDTCYTKCytokinetics says Tirasemtiv increases muscle force, improves grip strength
Cytokinetics announced that data from preclinical research relating to Tirasemtiv in mouse models of spinal muscular atrophy were presented at the 2014 Annual Spinal Muscular Atrophy Conference in National Harbor, Maryland. In these models, Tirasemtiv increased muscle force and improved grip strength, grid hang time, and resistance to fatigue.
News For CYTK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 30, 2015
16:19 EDTCYTKCytokinetics sees initiating phase 3 tirasemtiv program in Q2
Cytokinetics (CYTK) expects to initiate a phase III clinical development program for tirasemtiv in patients with ALS in Q2. Cytokinetics expects to initiate a phase II trial of CK-2127107 in patients with SMA in 2H. Cytokinetics expects results from COSMIC-HF to be available in 2H. Cytokinetics expects to continue joint development activities in collaboration with Amgen (AMGN) directed to the potential advancement of omecamtiv mecarbil to phase III clinical development.
16:17 EDTCYTKCytokinetics reports Q1 EPS (23c), may not compare to consensus (12c)
Reports Q1 revenue $4.41M, may not compare to consensus $10.08M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use